Cannabinoid receptor ligand bias: implications in the central nervous system

- Cannabinoid receptors are pleiotropically-coupled GPCRs.
- Few studies quantify cannabinoid bias using Black and Leff's operational model.
- Correlations between cannabinoid bias in vitro and in vivo are just being measured.
- Understanding cannabinoid bias could yield effective cannabinoid-based drugs.

The G protein-coupled cannabinoid receptors CB1, CB2, GPR18, and GPR55 regulate neurotransmission, pain, and inflammation and have been intensively investigated as potential drug targets. Each of these GPCRs is coupled to multiple effector proteins mediating divergent cellular signals. The ligand bias of cannabinoid-targeted compounds is only beginning to be quantified. Research into cannabinoid bias is now revealing correlations between bias in cell culture and functional outcomes in vivo. We present an example study of cannabinoid bias in the context of Huntington disease. In future, an understanding of cannabinoid receptor structure and quantification of ligand bias will optimize drug selection matched to patient population and disease.